Does lowering LDL-related lipoproteins (LDL-C or ApoB/LDL-P) meaningfully reduce cardiovascular disease and related outcomes risk for most people?
The shows debate whether lowering LDL-related particles substantially cuts cardiovascular events or has only minimal impact on heart disease and stroke risk. Over this year, Layne Norton (The Peter Attia Drive) and Michael Davidson (The Peter Attia Drive) have argued that lower LDL levels causally reduce disease risk. Across the same period, David Jockers (Dr. Jockers Functional Nutrition) and Gary Brecka (The Ultimate Human) have claimed that lowering LDL offers little overall protection.
Lowering LDL-related particles substantially lowers cardiovascular and related disease risk for most people.
Davidson states that every one millimole per liter, or about 38.8 mg/dL, reduction in LDL cholesterol yields a 22% relative risk reduction in cardiovascular events. Norton and Attia describe regressions and Mendelian randomization where identical risk reductions appear per unit LDL lowering, regardless of genetic variant or treatment method. Davidson argues that LDL is a causal factor that should be treated early, noting genomic data that lifelong LDL below about 80 mg/dL prevents heart disease. Otvos reports that when LDL particle number and LDL cholesterol disagree, cardiovascular risk follows the particle count, not the cholesterol concentration.
14 claims, in their words
-
“there was a regression. They looked at each, you know, one millimole reduction. So regardless of the variant, same reduction. And in the drug trials, the statin trials, regardless of how the statins worked, Also, with surgeries like, I think it was a little bypass or things that reduce LDL through absorption.”
-
“If you lower LDL before you have a heart attack, it's very effective. If you have a heart attack and you lower LDL, it still has benefit. But once you have heart failure, there's no benefit to lowering LDL. And so the earlier you start, the better.”
-
“For a one millimole, which is 38.8 milligrams per deciliter of LDL, you get a 22% relative risk reduction.”
-
“It's linear, right. But absolute is the key, not percent. You got to look at the absolute LDL lowering.”
-
“how many more trials do you need to show that LDL, no matter how you lower it, results in a clinical benefit?”
-
“In the first year of treatment, you get half the benefit at best. It takes time for the lines to separate.”
-
“all of these regressions are independent of how you do it. The Mendelian randomization says we're going to lower it genetically. ... So again, it speaks to this idea that reinforces the causality of LDL, because independent of how it's lowered, you're getting the same effects.”
-
“everything else being equal, having your LDL lower is better, all things being equal to having it higher.”
-
“Whenever there's a discrepancy in one direction or another, the cardiovascular risk tracks with the particle number, not the cholesterol.”
-
“We don't wait for stroke and heart failure to treat hypertension. We don't wait for blindness and kidney disease to treat diabetes. So I don't know why LDL gets this Stepchild type of role when it comes to how we manage, but it is causal and we know that.”
-
“the data says that if you keep your LDL below 80 throughout your lifetime, You don't get heart disease.”
-
“We have this path in right now today, which is the mainstream, is that you wait till someone has significant plaque buildup or even a heart attack or a stroke, then you treat super aggressively to get the LDL down. But we know from genomics that if you have a low LDL throughout your whole lifetime, it prevents heart disease”
-
“LDL is a dementia risk factor.”
-
“even with those LDL effects, which, which, which are not favorable, LDL predicts cardio adverse cardiovascular endpoints. But I believe that.”
Lowering LDL-related particles has minimal or limited impact on cardiovascular and related disease risk.
Jockers says studies show that lowering LDL cholesterol has only a very minimal effect on reducing heart disease and stroke risk. He adds that LDL lowering may offer some benefit mainly for people who have already had heart disease or strokes. Brecka reports that in twenty-two years reviewing mortality claims, every centenarian death he saw involved clinically elevated LDL cholesterol at the time of death. Brecka also says that when clients had high LDL cholesterol but triglycerides at or below 75 mg/dL, his group extended their projected life expectancy.
4 claims, in their words
-
“studies show that lowering LDL cholesterol has a very minimal effect on reducing your risk of heart disease and stroke.”
-
“studies show that lowering LDL cholesterol has a very minimal effect on reducing your risk of heart disease and stroke. There may be some benefit to doing it for people that have already had heart disease and strokes”
-
“in 22 years in the mortality space, we didn't process a single death claim on a centenarian, someone over the age of 100, that did not have clinically elevated levels of LDL cholesterol at the time of their death.”
-
“if you had low triglycerides, 75 milligrams per deciliter or less, and you had high LDL cholesterol, we would extend your life expectancy.”
Listeners of “Lowering LDL-related particles has minimal or limited impact on cardiovascular and related disease risk.” have not heard
Listeners of these shows have not heard Norton’s description of regressions where each one millimole LDL reduction produced similar risk drops across genetic, drug, and surgical lowering. They have not heard Davidson’s point that absolute LDL reduction, not just percentage change, tracks linearly with cardiovascular benefit across therapies. They have not heard Davidson list multiple drug mechanisms showing that no matter how LDL is lowered, trials report clinical benefit. They have not heard Davidson cite genomic data that lifelong LDL below about 80 mg/dL prevents heart disease in observed populations.
10 unanswered arguments, in their words
-
“all of these regressions are independent of how you do it. The Mendelian randomization says we're going to lower it genetically. ... So again, it speaks to this idea that reinforces the causality of LDL, because independent of how it's lowered, you're getting the same effects.”
-
“Whenever there's a discrepancy in one direction or another, the cardiovascular risk tracks with the particle number, not the cholesterol.”
-
“We don't wait for stroke and heart failure to treat hypertension. We don't wait for blindness and kidney disease to treat diabetes. So I don't know why LDL gets this Stepchild type of role when it comes to how we manage, but it is causal and we know that.”
-
“even with those LDL effects, which, which, which are not favorable, LDL predicts cardio adverse cardiovascular endpoints. But I believe that.”
-
“everything else being equal, having your LDL lower is better, all things being equal to having it higher.”
-
“there was a regression. They looked at each, you know, one millimole reduction. So regardless of the variant, same reduction. And in the drug trials, the statin trials, regardless of how the statins worked, Also, with surgeries like, I think it was a little bypass or things that reduce LDL through absorption.”
-
“We have this path in right now today, which is the mainstream, is that you wait till someone has significant plaque buildup or even a heart attack or a stroke, then you treat super aggressively to get the LDL down. But we know from genomics that if you have a low LDL throughout your whole lifetime, it prevents heart disease”
-
“It's linear, right. But absolute is the key, not percent. You got to look at the absolute LDL lowering.”
-
“how many more trials do you need to show that LDL, no matter how you lower it, results in a clinical benefit?”
-
“the data says that if you keep your LDL below 80 throughout your lifetime, You don't get heart disease.”
Listeners of “Lowering LDL-related particles substantially lowers cardiovascular and related disease risk for most people.” have not heard
Listeners of these shows have not heard Brecka’s claim that high LDL with triglycerides at or below 75 mg/dL led him to extend a client’s life expectancy estimate.
1 unanswered argument, in their words
-
“if you had low triglycerides, 75 milligrams per deciliter or less, and you had high LDL cholesterol, we would extend your life expectancy.”
One side leans on regression and lifelong-low-LDL genomics showing consistent event reduction per unit LDL drop, which Brecka and Jockers never address. The other side stresses centenarian data and high-LDL plus low-triglyceride longevity projections, which Attia’s guests do not directly confront.
3 arguments the other side has addressed
“studies show that lowering LDL cholesterol has a very minimal effect on reducing your risk of heart disease and stroke.”
“If you lower LDL before you have a heart attack, it's very effective. If you have a heart attack and you lower LDL, it still has benefit. But once you have heart failure, there's no benefit to lowering LDL. And so the earlier you start, the better.”
“studies show that lowering LDL cholesterol has a very minimal effect on reducing your risk of heart disease and stroke. There may be some benefit to doing it for people that have already had heart disease and strokes”
“If you lower LDL before you have a heart attack, it's very effective. If you have a heart attack and you lower LDL, it still has benefit. But once you have heart failure, there's no benefit to lowering LDL. And so the earlier you start, the better.”
“If you lower LDL before you have a heart attack, it's very effective. If you have a heart attack and you lower LDL, it still has benefit. But once you have heart failure, there's no benefit to lowering LDL. And so the earlier you start, the better.”
“studies show that lowering LDL cholesterol has a very minimal effect on reducing your risk of heart disease and stroke. There may be some benefit to doing it for people that have already had heart disease and strokes”
- Oct 17, 2026 2 new claims (The Peter Attia Drive).
- Oct 13, 2026 Gary Brecka moved from “Yes, small dense LDL particles are more atherogenic than large buoyant ones.” to “Lowering LDL-related particles has minimal or limited impact on cardiovascular and related disease risk.”.
- Oct 13, 2026 David Jockers moved from “Yes, small dense LDL particles are more atherogenic than large buoyant ones.” to “Lowering LDL-related particles has minimal or limited impact on cardiovascular and related disease risk.”.
- Oct 13, 2026 Jim Otvos moved from “No, LDL particle number rather than size determines cardiovascular risk.” to “Lowering LDL-related particles substantially lowers cardiovascular and related disease risk for most people.”.
- Oct 13, 2026 David Jockers (Dr. Jockers Functional Nutrition, 2026-02-05) addressed an argument by Michael Davidson.
- Oct 13, 2026 Michael Davidson (The Peter Attia Drive, 2026-09-14) addressed an argument by David Jockers.
- Oct 13, 2026 Michael Davidson (The Peter Attia Drive, 2026-09-14) addressed an argument by David Jockers.
- Oct 13, 2026 19 new claims (Dr. Jockers Functional Nutrition, The Peter Attia Drive, The Ultimate Human).
- Oct 7, 2026 Published: cleared the gate.
- Oct 7, 2026 Jim Otvos moved from “small dense LDL particles are inherently more atherogenic than large buoyant ones.” to “No, LDL particle number rather than size determines cardiovascular risk.”.
- Oct 7, 2026 Jim Otvos (The Peter Attia Drive, 2026-08-03) addressed an argument by Gary Brecka.
- Oct 7, 2026 Gary Brecka (The Ultimate Human, 2026-08-13) addressed an argument by Jim Otvos.
- Oct 7, 2026 46 new claims (Dr. Jockers Functional Nutrition, Science Vs, Huberman Lab, The Peter Attia Drive, The Ultimate Human, unPAUSED with Dr. Mary Claire Haver).
Published because: 3 shows, 2 positions, 252 days of debate. Questions publish only when claims come from at least three shows, at least two positions are held by different people, and the debate has lasted two weeks.
Pairs are matched by content across different episodes and shows; no exchange between these speakers took place unless both quotes come from the same episode.
The prose on this page is written by a model from the quotes shown, and every sentence of it rests on quotes you can open; sentences that could not be traced to a quote were removed before publishing. Positions are placed from each speaker's own words. Evidence labels say what the speaker cited, never whether it is true.
7 episodes behind this page
- 2026-09-28The Peter Attia Drive — #409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.
- 2026-09-14The Peter Attia Drive — #407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.
- 2026-08-13The Ultimate Human — 295. Methylation Test & MTHFR Gene - Healf Experience Wellbeing Event 2026 in London
- 2026-08-03The Peter Attia Drive — #402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.
- 2026-07-16The Ultimate Human — 287. Live at the Southern Utah Holistic Health Summit 2026
- 2026-02-05Dr. Jockers Functional Nutrition — The Hidden Dangers of Cholesterol Medications (Doctors Don't Tell You This!)
- 2026-01-19The Peter Attia Drive — #380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D.
The week's bottom lines, in your inbox
One email a week: the stories that mattered and what they actually mean. Free.